Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) EBITDA Margin (2020 - 2025)

Barinthus Biotherapeutics' EBITDA Margin history spans 6 years, with the latest figure at 1283600.0% for Q2 2025.

  • For Q2 2025, EBITDA Margin changed N/A year-over-year to 1283600.0%; the TTM value through Dec 2025 reached 17769.09%, down 1734351.0%, while the annual FY2024 figure was 425.76%, 745479.0% up from the prior year.
  • EBITDA Margin reached 1283600.0% in Q2 2025 per BRNS's latest filing, down from 4750.63% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1666800.0% in Q4 2021 to a low of 1283600.0% in Q2 2025.
  • Average EBITDA Margin over 5 years is 22289.9%, with a median of 2870.7% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: soared 166952119bps in 2021, then crashed -166718862bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 1666800.0% in 2021, then crashed by -100bps to 388.62% in 2022, then plummeted by -1304bps to 5455.09% in 2023, then soared by 100bps to 7.09% in 2024, then tumbled by -18092575bps to 1283600.0% in 2025.
  • Per Business Quant, the three most recent readings for BRNS's EBITDA Margin are 1283600.0% (Q2 2025), 4750.63% (Q1 2025), and 7.09% (Q3 2024).